CLINDAMYCIN INJECTION USP SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)

Dostupné s:

SANDOZ CANADA INCORPORATED

ATC kód:

J01FF01

INN (Mezinárodní Name):

CLINDAMYCIN

Dávkování:

150MG

Léková forma:

SOLUTION

Složení:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 150MG

Podání:

INTRAVENOUS

Jednotky v balení:

60ML/120ML

Druh předpisu:

Prescription

Terapeutické oblasti:

LINCOMYCINS

Přehled produktů:

Active ingredient group (AIG) number: 0105830002; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2005-08-05

Charakteristika produktu

_CLINDAMYCIN INJECTION USP (Clindamycin Injection) _
_ Page 1 of 41 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR CLINDAMYCIN INJECTION USP
Clindamycin Injection
Sterile Solution, 150 mg / mL clindamycin (as clindamycin phosphate),
Intravenous,
Intramuscular
USP
Antibiotic
Sandoz Canada Inc.
110 rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Date of Initial Authorization:
January 15, 1999
Date of Revision:
June 2, 2022
Submission Control Number: 262482
_CLINDAMYCIN INJECTION USP (Clindamycin Injection) _
_ Page 2 of 41 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
06/2022
7 WARNINGS AND PRECAUTIONS, Renal
06/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...............................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1
Pediatrics.................................................................................................................
5
1.2 Geriatrics
.................................................................................................................
5
2
CONTRAINDICATIONS
.......................................................................................................
5
4
DOSAGE AND
ADMINISTRATION........................................................................................
6
4.1 Dosing Considerations
.............................................................................................
6
4.2 Recommended Dose and Dosage Adjustment
.......................................................... 6
4.3